V3 versican isoform expression alters the phenotype of melanoma cells and their tumorigenic potential

International Journal of Cancer

Volumn 114, Issue 6, 2005, Pages 879-886

  Serra, Montserrat ^a   Miquel, Laia ^a   Domenzain, Clelia ^a   Docampo, María José ^a   Fabra, Angels ^b   Wight, Thomas N ^c   Bassols, Anna ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b Institut de Recerca Oncologica   (Spain)

^c HOPE HEART INSTITUTE   (United States)

Author keywords

Hyaluronan; Melanoma; Proteoglycan; Tumorigenesis; Versican

Indexed keywords

HERMES ANTIGEN; HYALURONIC ACID; ISOPROTEIN; RETROVIRUS VECTOR; VERSICAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CARCINOGENICITY; CELL ADHESION; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; MELANOMA; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; WESTERN BLOTTING;

ANIMALS; ANTIGENS, CD44; CELL ADHESION; CELL MOVEMENT; DOGS; GENE EXPRESSION PROFILING; HUMANS; HYALURONIC ACID; LECTINS, C-TYPE; MELANOMA; PHENOTYPE; PROTEIN ISOFORMS; PROTEOCHONDROITIN SULFATES; SKIN NEOPLASMS; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED; UP-REGULATION; VERSICANS;

EID: 17044403883     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20813     Document Type: Article

References (42)

1. Wight TN. Versican: a versatile extracellular matrix proteoglycan in cell biology. Curr Opin Cell Biol 2002;14:617-23.
2. Dours-Zimmermann MT, Zimmermann DR. A novel glycosaminoglycan attachment domain identified in two alternative splice variants of human versican. J Biol Chem 1994;269:32992-8.
3. Iozzo RV. Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem 1998;67:609-52.
4. Zimmermann DR. Versican. In: Iozzo R, ed. Proteoglycans: structure, biology and molecular interactions. New York: Marcel Dekker, 2000. 327-41.
5. Matsumoto K, Shionyu M, Go M, Shimizu K, Shinomura T, Kimata K, Watanabe H. Distinct interaction of versican/PG-M with hyaluronan and link protein. J Biol Chem 2003;278:41205-12.
6. Ito K, Shinomura T, Zako M, Ujita M, Kimata K. Multiple forms of mouse PG-M, a large chondroitin sulfate proteoglycan generated by alternative splicing. J Biol Chem 1995;270:958-65.
7. Touab M, Villena J, Barranco C, Arumi-Uria M, Bassols A. Versican is differentially expressed in human melanoma and may play a role in tumor development. Am J Pathol 2002;160:549-57.
8. Paulus W, Baur I, Dours-Zimmermann MT, Zimmermann DR. Differential expression of versican isoforms in brain tumors. J Neuropathol Exp Neurol 1996;55:528-33.
9. Ricciardelli C, Mayne K, Sykes PJ, Raymond WA, McCaul K, Marshall VR, Horsfall DJ. Elevated levels of versican but not decorin predict disease progression in early-stage prostate cancer. Clin Cancer Res 1998;4:963-71.
10. Sakko AJ, Ricciardelli C, Mayne K, Tilley WD, LeBaron RG, Horsfall DJ. Versican accumulation in human prostatic fibroblast cultures is enhanced by prostate cancer cell-derived transforming growth factor beta1. Cancer Res 2001;61:926-30.
11. Nara Y, Kato Y, Torii Y, Tsuji Y, Nakagaki S, Goto S, Isobe H, Nakashima N, Takeuchi J. Immunohistochemical localization of extracellular matrix components in human breast tumours with special reference to PG-M/versican. Histochem J 1997;29:21-30.
12. Brown LF, Guidi AJ, Schnitt SJ, Van De WL, Iruela-Arispe ML, Yeo TK, Tognazzi K, Dvorak HF. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin Cancer Res 1999;5:1041-56.
13. Ricciardelli C, Brooks JH, Suwiwat S, Sakko AJ, Mayne K, Raymond WA, Seshadri R, LeBaron RG, Horsfall DJ. Regulation of stromal versican expression by breast cancer cells and importance to relapse-free survival in patients with node-negative primary breast cancer. Clin Cancer Res 2002; 8:1054-60.
14. Isogai Z, Shinomura T, Yamakawa N, Takeuchi J, Tsuji T, Heinegard D, Kimata K. 2B1 antigen characteristically expressed on extracellular matrices of human malignant tumors is a large chondroitin sulfate proteoglycan, PG-M/versican. Cancer Res 1996;56:3902-8.
15. Zhang Y, Cao L, Yang BL, Yang BB. The G3 domain of versican enhances cell proliferation via epidermial growth factor-like motifs. J Biol Chem 1998;273:21342-51.
16. Wu Y, Zhang Y, Cao L, Chen L, Lee V, Zheng PS, Kiani C, Adams ME, Ang LC, Paiwand F, Yang BB. Identification of the motif in versican G3 domain that plays a dominant-negative effect on astrocytoma cell proliferation through inhibiting versican secretion and binding. J Biol Chem 2001;276:14178-86.
17. Cattaruzza S, Schiappacassi M, Kimata K, Colombatti A, Perris R. The globular domains of PG-M/versican modulate the proliferation-apoptosis equilibrium and invasive capabilities of tumor cells. FASEB J 2004;18:779-81.
18. Lemire JM, Merrilees MJ, Braun KR, Wight TN. Overexpression of the V3 variant of versican alters arterial smooth muscle cell adhesion, migration, and proliferation in vitro. J Cell Physiol 2002;190:38-45.
19. Houghton AN, Real FX, Davis LJ, Cordon-Cardo C, Old LJ. Phenotypic heterogeneity of melanoma. Relation to the differentiation program of melanoma cells. J Exp Med 1987;165:812-29.
20. Wolfe LG, Oliver JL, Smith BB, Toivio-Kinnucan MA, Powers RD, Brawner WR, Henderson RA, Hankes GH. Biologic characterization of canine melanoma cell lines. Am J Vet Res 1987;48:1642-8.
21. Serra M, Pastor J, Domenzain C, Bassols A. Effect of transforming growth factor-beta1, insulin-like growth factor-I, and hepatocyte growth factor on proteoglycan production and regulation in canine melanoma cell lines. Am J Vet Res 2002;63:1151-8.
22. Alldinger S, Baumgartner W, Kremmer E, Fonfara S. Characterization of a canine CD44 specific monoclonal antibody. Zentralbl Veterinarmed A 1999;46:19-32.
23. Fischer JW, Kinsella MG, Hasenstab D, Clowes AW, Wight TN. Cell-mediated transfer of proteoglycan genes. Methods Mol Biol 2001;171:261-9.
24. Lemire JM, Braun KR, Maurel P, Kaplan ED, Schwartz SM, Wight TN. Versican/PG-M isoforms in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1999;19:1630-9.
25. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-5.
26. Koochekpour S, Pilkington GJ, Merzak A. Hyaluronic acid/CD44H interaction induces cell detachment and stimulates migration and invasion of human glioma cells in vitro. Int J Cancer 1995;63:450-4.
27. Savani RC, Cao G, Pooler PM, Zaman A, Zhou Z, DeLisser HM. Differential involvement of the hyaluronan (HA) receptors CD44 and receptor for HA-mediated motility in endothelial cell function and angiogenesis. J Biol Chem 2001;276:36770-8.
28. Underhill CB, Nguyen HA, Shizari M, Culty M. CD44 positive macrophages take up hyaluronan during lung development. Dev Biol 1993;155:324-36.
29. Yamagata M, Kimata K. Repression of a malignant cell-substratum adhesion phenotype by inhibiting the production of the anti-adhesive proteoglycan, PG-M/versican. J Cell Sci 1994;107 (Pt 9):2581-90.
30. Perissinotto D, Iacopetti P, Bellina I, Doliana R, Colombatti A, Pettway Z, Bronner-Fraser M, Shinomura T, Kimata K, Morgelin M, Lofberg J, Perris R. Avian neural crest cell migration is diversely regulated by the two major hyaluronan-binding proteoglycans PG-M/versican and aggrecan. Development 2000;127:2823-42.
31. Lemire JM, Merrilees MJ, Braun KR, Wight TN. Overexpression of the V3 variant of versican alters arterial smooth muscle cell adhesion, migration, and proliferation in vitro. J Cell Physiol 2002;190:38-45.
32. Hinek A, Braun KR, Liu K, Wang Y, Wight TN. Retrovirally mediated overexpression of versican v3 reverses impaired elastogenesis and heightened proliferation exhibited by fibroblasts from Costello syndrome and Hurler disease patients. Am J Pathol 2004;164:119-31.
33. Wu Y, Chen L, Zheng PS, Yang BB. beta 1-Integrin-mediated glioma cell adhesion and free radical-induced apoptosis are regulated by binding to a C-terminal domain of PG-M/versican. J Biol Chem 2002;277:12294-301.
34. Yang BL, Cao L, Kiani C, Lee V, Zhang Y, Adams ME, Yang BB. Tandem repeats are involved in G1 domain inhibition of versican expression and secretion and the G3 domain enhances glycosaminoglycan modification and product secretion via the complement-binding protein-like motif. J Biol Chem 2000;275:21255-61.
35. Zheng PS, Wen J, Ang LC, Sheng W, Viloria-Petit A, Wang Y, Wu Y, Kerbel RS, Yang BB. Versican/PG-M G3 domain promotes tumor growth and angiogenesis. FASEB J 2004;18:754-6.
36. Wu Y, Chen L, Cao L, Sheng W, Yang BB. Overexpression of the C-terminal PG-M/versican domain impairs growth of tumor cells by intervening in the interaction between epidermal growth factor receptor and β1-integrin. J Cell Sci 2004;117:2227-37.
37. Faassen AE, Schrager JA, Klein DJ, Oegema TR, Couchman JR, McCarthy JB. A cell surface chondroitin sulfate proteoglycan, immunologically related to CD44, is involved in type I collagen-mediated melanoma cell motility and invasion. J Cell Biol 1992;116:521-31.
38. Knudson W. Tumor-associated hyaluronan. Providing an extracellular matrix that facilitates invasion. Am J Pathol 1996;148:1721-6.
39. Thomas L, Byers HR, Vink J, Stamenkovic I. CD44H regulates tumor cell migration on hyaluronate-coated substrate. J Cell Biol 1992;118:971-7.
40. Ichikawa T, Itano N, Sawai T, Kimata K, Koganehira Y, Saida T, Taniguchi S. Increased synthesis of hyaluronate enhances motility of human melanoma cells. J Invest Dermatol 1999;113:935-9.
41. Ahrens T, Assmann V, Fieber C, Termeer C, Herrlich P, Hofmann M, Simon JC. CD44 is the principal mediator of hyaluronic-acid-induced melanoma cell proliferation. J Invest Dermatol 2001;116:93-101.
42. Itano N, Atsumi F, Sawai T, Yamada Y, Miyaishi O, Senga T, Hamaguchi M, Kimata K. Abnormal accumulation of hyaluronan matrix diminishes contact inhibition of cell growth and promotes cell migration. Proc Natl Acad Sci USA 2002;99:3609-14.